Perrigo
This article was originally published in The Tan Sheet
Executive Summary
Allegan, Mich.-based generics firm saw "strong sales of loratadine D-24, the store brand equivalent to Claritin D-24; had strong initial shipments of loratadine syrup and loratadine quick-dissolve tablets; and experienced growth in the vitamin category" during the third quarter ended March 27, Perrigo CEO David Gibbons reports in an April 23 earnings call. Overall net sales grew 14% to $230.7 mil. compared to the year-ago quarter. Results were driven by "new products launched earlier in the year, new products shipping in the current period, and revenue from Peter Black Pharmaceuticals, a UK-based nutritional business acquired in December 2003"...
You may also be interested in...
Perrigo Children’s Loratadine Syrup Pulled: 2.8 Mil. Bottles In Play
Perrigo is recalling all lots of loratadine syrup from retailer and wholesaler channels because of manufacturing issues
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.